See more : Kangwon Land, Inc. (035250.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Alzamend Neuro, Inc. (ALZN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alzamend Neuro, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Celxpert Energy Corporation (3323.TWO) Income Statement Analysis – Financial Results
- Ajanta Soya Limited (AJANTSOY.BO) Income Statement Analysis – Financial Results
- MKVENTURES CAPITAL LIMITED (MKVENTURES.BO) Income Statement Analysis – Financial Results
- Morgan Advanced Materials plc (MCRUF) Income Statement Analysis – Financial Results
- Takeda Pharmaceutical Company Limited (4502.T) Income Statement Analysis – Financial Results
Alzamend Neuro, Inc. (ALZN)
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.74K | 23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.74K | -23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.46M | 7.45M | 5.20M | 1.31M | 1.07M | 3.70M | 323.40K | 275.05K | 0.00 |
| General & Administrative | 3.24M | 6.68M | 7.12M | 3.64M | 3.35M | 1.31M | 545.12K | 942.51K | 69.46K |
| Selling & Marketing | 247.33K | 742.60K | 17.65K | 0.00 | 0.00 | 0.00 | 29.91K | 330.84K | 0.00 |
| SG&A | 3.48M | 7.42M | 7.12M | 3.64M | 3.35M | 1.31M | 575.03K | 1.27M | 69.46K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Cost & Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Interest Income | 0.00 | 7.70 | 46.52 | 1.71K | 13.93K | 146.39K | 33.23K | 21.50K | 0.00 |
| Interest Expense | 10.10K | 7.70K | 46.52K | 158.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74K | 23.07K | 3.55K | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| EBITDA | -9.89M | -14.85M | -12.32M | 0.00 | 0.00 | 0.00 | 7.34K | -21.50K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.94M | -14.87M | -12.32M | -4.95M | -4.42M | -5.01M | -898.43K | -1.55M | -69.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.10K | -7.70K | -42.52K | -94.68K | 13.93K | 146.39K | -33.23K | -21.50K | 0.00 |
| Income Before Tax | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -931.66K | -1.57M | -69.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -144.83K | 42.52K | 157.10K | -13.93K | -146.39K | -898.43K | -21.50K | 0.00 |
| Net Income | -9.95M | -14.88M | -12.40M | -5.20M | -4.40M | -4.86M | -931.66K | -1.57M | -69.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.72 | -22.89 | -20.92 | -10.75 | -9.26 | -12.40 | -1.64 | -8.18 | -0.42 |
| EPS Diluted | -14.70 | -22.89 | -20.88 | -10.74 | -9.25 | -12.40 | -1.64 | -8.18 | -0.42 |
| Weighted Avg Shares Out | 676.00K | 650.00K | 593.00K | 484.00K | 475.00K | 392.00K | 568.70K | 192.00K | 165.00K |
| Weighted Avg Shares Out (Dil) | 676.57K | 650.13K | 593.97K | 484.33K | 475.02K | 392.29K | 568.70K | 192.01K | 165.30K |
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it submitted...
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has...
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has...
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it will be presenting at the 12th Annual LD Micro Invitational,...
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has submitted a Pre-IND (investigational new drug) meeting request for...
3 Penny Stocks to Add to Your Watchlist This Coming Week
Which penny stocks are you watching right now? The post 3 Penny Stocks to Add to Your Watchlist This Coming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that the first patient with mild to moderate Alzheimer’s disease (“Alzheimer’s”) has...
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that Digital Power Lending, LLC (“DPL”), a wholly owned...
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) announced today its wholly owned subsidiary, Digital Power Lending, LLC (“DP Lending”) has made an additional investment in Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”),...
Source: https://incomestatements.info
Category: Stock Reports